There have been significant advances in the treatment of multiple sclerosis (MS) in recent
years, but further improvement in therapy is required as not all patients have responded
optimally. An approach to enhancing MS treatment is to combine drugs that impact on
different aspects of the disease process. We have described that the tetracycline derivative,
minocycline, attenuates the severity of experimental autoimmune encephalomyelitis (EAE),
a model of MS. Here, we have evaluated the combination of minocycline and glatiramer …